

ONCODAILY MEDICAL JOURNAL

abstract

Immune-Related Endocrine Adverse Events from Checkpoint Inhibitors: A Systematic Review of Clinical Outcomes and Management

Basant Samy Aamer

DOI: 10.69690/ODMJ-018-3101-6463

AMSTRO

Asia and Middle East Society of
Therapeutic Radiation and Oncology

Affiliated with ASTF

Asia and Middle East Society for Radiation Therapy and Oncology, 2026

abstract

Immune-Related Endocrine Adverse Events from Checkpoint Inhibitors: A Systematic Review of Clinical Outcomes and Management

Authors: Basant Samy Aamer

Affiliation: Oman International Hospital, Muscat, Oman

DOI: 10.69690/ODMJ-018-3101-6463

Introduction: Immune checkpoint inhibitors (ICIs) improve survival across multiple malignancies but frequently trigger immune-related endocrine adverse events (irEA-E), which can be irreversible and under-recognized.

Methodology: A structured review of randomized trials, cohort studies, and meta-analyses published between 2018 and 2025 was conducted to evaluate endocrine toxicities associated with anti-PD-1/PD-L1 and anti-CTLA-4 agents. Reported outcomes included incidence, timing, reversibility, and management strategies.

Results: Thyroid dysfunction (5–20%) was the most frequently reported endocrine toxicity, followed by hypophysitis (1–15%), adrenal insufficiency (0.5–2%), and autoimmune diabetes (0.2–1.5%). Onset typically occurs weeks to months after therapy initiation. Most events are permanent and require long-term hormone replacement. High-

dose corticosteroids are generally reserved for mass-effect hypophysitis or systemic grade ≥ 3 immune-related adverse events.

Conclusion: The evaluation of the primary tumor process extent revealed: multifocality in 63 (48%) patients, involvement of neck lymph nodes in 115 (88%), lung metastases in 14 (11%). Adjuvant RIT to ablate residual thyroid tissue and reduce the risk of recurrence were performed at an average ^{131}I activity of 2 GBq (1.1–4 GBq), therapy of lung metastases with ^{131}I 4 GBq (1.83–5 GBq). Out of 14 patients with lung metastases, 3 patients had a radioiodine refractory process. Lung metastases were associated with an advanced primary process (T3–4, N1b) and high TTG-stimulated thyroglobulin levels (from 118 ng/ml to >5,000 ng/ml).

Conflict of interests: The authors declare no conflict of interests.

Funding: This research received no specific grant from

any funding agency in the public, commercial, or not-for-profit sectors.

Licence: © Author(s) 2026. This is an open access article distributed under the terms of the Creative Commons Attribution 4.0 International License (CC BY 4.0), which permits unrestricted use, distribution, and reproduction in any medium, and unrestricted adaptation and reuse, including for commercial purposes, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.

To view a copy of this license, visit <https://creativecommons.org/licenses/by/4.0/>.